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Background: Oncologic and functional outcomes after radical prostatectomy (RP) can vary between surgeons to a
greater extent than is expected by chance. We sought to examine the effects of surgeon variation on functional
and oncologic outcomes for patients undergoing RP for prostate cancer in a European center.
Methods: The study comprised 1,280 men who underwent open retropubic RP performed by one of nine surgeons at
an academic institution in Sweden between 2001 and 2008. Potency and continence outcomes were measured
preoperatively and 18 months postoperatively by patient-administered questionnaires. Biochemical recurrence (BCR)
was defined as a prostate-specific antigen (PSA) value > 0.2 ng/mL with at least one confirmatory rise. Multivariable
random effect models were used to evaluate heterogeneity between surgeons, adjusting for case mix (age, PSA,
pathological stage and grade), year of surgery, and surgical experience.
Results: Of 679 men potent at baseline, 647 provided data at 18 months with 122 (19%) reporting potency. We found
no evidence for heterogeneity of potency outcomes between surgeons (P = 1). The continence rate for patients at
18 months was 85%, with 836 of the 979 patients who provided data reporting continence. There was statistically
significant heterogeneity between surgeons (P = 0.001). We did not find evidence of an association between surgeons’
adjusted probabilities of functional recovery and 5-year probability of freedom from BCR.
Conclusions: Our data support previous studies regarding a large heterogeneity among surgeons in continence
outcomes for patients undergoing RP. This indicates that some patients are receiving sub-optimal care. Quality assurance
measures involving performance feedback, should be considered. When surgeons are aware of their outcomes, they can
improve them to provide better care to patients.
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Radical prostatectomy (RP) with curative intent is the
most common treatment for men with localized prostate
cancer [1]. A prospective, randomized Swedish trial
demonstrated that surgery provides a survival benefit in
men with mainly clinically diagnosed, palpable tumors
when compared to watchful waiting [2]. However, surgi-
cal treatment is associated with long-term morbidity,* Correspondence: carlssos@mskcc.org
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reproduction in any medium, provided the ormainly erectile dysfunction (ED) and urinary incontin-
ence, which affect a patient’s quality of life (QoL) sub-
stantially [3,4].
Previous studies performed in high-volume referral
centers in the United States (US) have shown that both
oncologic [5] and functional outcomes [6,7] after RP
vary between surgeons to a greater extent than is ex-
pected by chance. In the present validation study, we
sought to explore whether such heterogeneity exists in
long-term functional and oncologic outcomes among
surgeons in a European center who operate in a
population-based academic setting. Another rationale
for the present study is that there is limited data onl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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fore, the present study provides a unique opportunity to
explore any variability in outcomes as assessed by vali-
dated PRO instruments.Methods
The original database consisted of 1,447 men who were
scheduled for open retropubic RP at Sahlgrenska Univer-
sity Hospital in Göteborg, Sweden, during the study period
2001–2008, when standardized data recording into a qual-
ity assurance database was performed.
The quality control program was approved by the Ethical
Committee at Göteborg University in 2001. Patients were
mailed questionnaires, a cover letter with information re-
garding the quality assurance program, and a statement of
voluntary participation in the study.
Of the 58 patients excluded, 38 were enrolled in another
clinical RP trial (LAPPRO) [8], 4 underwent surgery outside
the university hospital, 7 did not undergo surgery (with 4
switching to radiotherapy and 3 receiving hormonal ther-
apy), and 9 did not undergo surgery but may have had
surgery elsewhere for unknown reasons (moved or loss-
to-follow-up). This left 1,389 patients in the cohort. Sur-
gery dates ranged from Jan 2, 2001 through July 16, 2008.
Biochemical recurrence (BCR) post-prostatectomy was
defined as a prostate-specific antigen (PSA) value >
0.2 ng/mL with at least one confirmatory rise. Mea-
surements were obtained from medical charts.
Of 1,389 patients, an additional 109 were excluded from
analysis since they were never administered any question-
naires, leaving 1,280 patients available for analysis of
functional outcomes. Patients responded to question-
naires regarding continence and potency on 4 occa-
sions, approximately 2 weeks preoperatively and at
6, 18, and 36 months after surgery.
Patients were administered questionnaires assessing
urinary continence using pads [9]. Continence was de-
fined as no leakage or occasional leakage associated
with physical activity requiring sporadic use of pads
(score 0–1 on a 0–4 point scale, where 2–4 implies in-
continence with regular use of pads).
Erectile function was assessed by the standardized
International Index of Erection Function questionnaire
IIEF-5 [10]. The IIEF-5 score consists of 5 items with 6
responses. The total score is the sum of the 5 items and
ranges from 5–25, the higher the score the better po-
tency. For patients missing responses for an item, the
sum of the remaining items was used. Potency was de-
fined as an IIEF-5 score of ≥ 17, which corresponds to
Rosen et al.’s categorization of mild ED (17–21) and no
ED (22–25) [10]. This also makes our study comparable
to functional outcomes reported in an earlier study by
Vickers et al. where postoperative potency was definedas 1 = normal, full erections and 2 = full, but dimin-
ished erections [6].
Missing data on potency status (potent/impotent)
and continence (incontinent/continent) at 18 months
were imputed following an algorithm assuming that
few men regain and then lose function as well as that
recovery of function can occur beyond 18 months. If a
patient was missing a questionnaire at 18 months but
reported potency at 6 months, he was assumed to be
potent at 18 months. Comparably, a patient reporting
impotence at 6 and 36 months was considered impo-
tent at 18 months. A similar approach was used for the
continence endpoint.
Patients reporting use of alprostadil injections for erect-
ile aid were categorized as impotent (3 men preopera-
tively, 222 men at 18 months, and 198 men at 36 months).
Men reporting use of PDE5-inhibitors were included in
the analysis.Statistics
Data on a total of 25 individual surgeons working at the
hospital during the study period were included in the
database. We analyzed patient-reported functional out-
comes for 9 surgeons who performed ≥ 20 surgeries dur-
ing the study period. Data for these surgeons were
entered both as random and fixed effects.
Logistic regression models were adjusted for age at sur-
gery, PSA at diagnosis, pathologic stage (pT0, pT2, pT3),
pathologic Gleason score (≤ 6, 7, ≥ 8), year of surgery, and
surgical experience. We defined surgical experience as a
variable that took into account both the surgeon’s prior
experience, i.e., number of RPs before 2001, and the annual
number of prostatectomies performed during the study
period [6]. To statistically test for heterogeneity, a random
effect following an inverse Gaussian distribution was in-
cluded in the model.
The logistic regression model used to predict the
probability of potency at 18 months was restricted to
men who were potent preoperatively and also adjusted
for the IIEF-5 score as a continuous variable. The
model for continence at 18 months was restricted to
men who were continent preoperatively. Since there
have been changes in patient characteristics as well as
operative technique, we also included year of surgery
as a covariate. Nerve sparing status was not included
in the model since it is a surgical decision. Take the
case of two surgeons, one of whom only spared nerves
if the cancer was very low risk and accordingly resected
far from the neurovascular bundles, the other of whom
only resected nerves for advanced disease. Overall, the
former surgeon would have far lower potency rates, but
adjusting for nerve sparing would lead to higher appar-
ent rates.
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model was used to model BCR rates following adjustment
for the same covariates as for functional outcomes. To
statistically test for heterogeneity, a shared frailty sur-
vival model was fitted.
For each surgeon studied, forest plots were created for
the adjusted predicted probability of potency and contin-
ence, respectively, using the mean value for the covariates
from the fixed regression model with a 95% confidence
interval.
A scatter plot was created for adjusted rates of contin-
ence and potency with the size of each surgeon’s data
point proportional to the number of RPs (prior experi-
ence and during the study period) performed by each
surgeon. Spearman’s rank correlation was applied to test
the correlation between surgeons’ adjusted probabilities
of potency and continence at 18 months as well as BCR.
Statistical analyses were performed using Stata v. 12.0
(Stata Corp, College Station, TX, USA).Table 1 Clinical characteristics for all patients who underwen
Age at surgery, median years (IQR)
PSA at diagnosis, median (IQR) ng/mL (Missing n=3)
Follow-up for biochemical recurrence, median years (IQR)
Pathological Gleason score (Missing n=2)
Nerve-sparing surgery (Missing n=3)
Surgical margins (Missing n=5)
Seminal vesicle invasion (Missing n=16)
Pathological stage (Missing n=7)
Preoperative erectile function (Missing n=241)
Postoperative erectile function at 18 months (Missing n=633)
Preoperative urinary function (Missing n=202)
Postoperative urinary function at 18 months (Missing n=301)
PSA = prostate-specific antigen, IQR = Inter Quartile Range.Results
Table 1 shows clinical characteristics for all 1,280 men who
underwent RP. The median age at surgery was 64 years.
Crude functional outcome rates per surgeon along with
prior experience and the number of cases operated upon
during the study period are shown in Table 2. Nine sur-
geons performed ≥ 20 surgeries during the study period,
with a maximum of 248 cases. The prior experience of
these surgeons ranged between 0 and 360 cases (Table 2).
Regarding functional outcomes, a total of 1,039 men
responded to the IIEF-5 questionnaire, with 679 report-
ing being potent preoperatively (65%). Data were avail-
able for 647 (95%) patients at 18 months with 122 (19%)
reporting potency (without alprostadil).
Crude potency rates at 18 months were higher for men
who underwent bilateral nerve-sparing RP (31.8%) and for
those < 60 years of age (45.7%) (data not shown).
Of the 1,078 patients who responded preoperatively to







≤ 6 593 (46.5)
7 624 (48.9)
≥ 8 59 (4.6)



















Table 2 Unadjusted functional outcome rates per surgeon (among preoperatively potent and continent men) in relation to prior experience and number of















18 months, n (%)
Continent at
18 months, n (%)
Incontinent at
18 months, n (%)
Missing continence
information at
18 months, n (%)
1 32 94 4 (9.1) 38 (86.4) 2 (4.5) 56 (78.9) 14 (19.7) 1 (1.4)
2 120 248 20 (15.9) 98 (77.8) 8 (6.3) 171 (86.8) 15 (7.6) 11 (5.6)
3 2 104 12 (20.0) 45 (75.0) 3 (5.0) 69 (76.7) 14 (15.6) 7 (7.8)
4 360 156 20 (24.1) 59 (71.1) 4 (4.8) 115 (84.6) 14 (10.3) 7 (5.1)
5 13 239 25 (19.4) 98 (76.0) 6 (4.7) 157 (83.1) 18 (9.5) 14 (7.4)
6 115 138 16 (19.3) 64 (77.1) 3 (3.6) 80 (66.1) 27 (22.3) 14 (11.6)
7 67 97 9 (16.1) 46 (82.1) 1 (1.8) 69 (82.1) 11 (13.1) 4 (4.8)
8 2 75 7 (20.6) 25 (73.5) 2 (5.9) 43 (71.7) 12 (20.0) 5 (8.3)
9 0 49 4 (13.8) 22 (75.9) 3 (10.3) 21 (58.3) 10 (27.8) 5 (13.9)
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836 were continent (85%). The degrees of incontinence
at 18 months among preoperatively continent men were
as follows: never urinary leakage (39.0%), sometimes
urinary leakage when coughing, sneezing or performing
physical exercise with sporadic use of pads (46.4%),
regular use of pads but they are not always wet (9.4%),
regular use of pads that are wet (3.3%), and constant
urinary leakage (1.7%).
Between-surgeon variation in functional outcomes is
shown in the forest plots for potency in Figure 1A and
continence in Figure 1B. For potency at 18 months, we
found no evidence for heterogeneity between surgeons
(random effects variance = 0.0002, P = 1). For contin-
ence at 18 months, there was a statistically significantA
Random effects variance = 0.0002, P = 1
C
Random effects variance 0.013349, P =0.484
Figure 1 Forest plots for the probability of functional and oncologic
postoperatively. B. Probability of continence at 18 months postoperatively.
Proportions (squared dots) and 95% confidence intervals (horizontal lines) a
surgery, PSA at diagnosis, pathological stage, pathologic Gleason score, year o
adjusted probability for all surgeons. Potency was defined as an IIEF-5 total sc
defined as urinary control with no leakage or sporadic use of pads due to leaheterogeneity between surgeons, (random effects variance
= 0.0318; 95% CI 0.0125 – 0.1649, P = 0.001) with contin-
ence rates varying from 70 to 93% between surgeons. For
BCR at a mean follow-up of 5.12 years (SD 0.07), hete-
rogeneity between surgeons was not observed (random
effects variance = 0.0133, P = 0.484) (Figure 1C).
The correlation between surgeons’ adjusted probabil-
ities of potency and continence was not statistically sig-
nificant (Spearman’s rho −0.20, P = 0.61) (Figure 2A).
Postoperatively, the 5-year probability of freedom from
BCR adjusted for case mix was 86%. We observed a weak
and non-significant association between surgeons’ ad-
justed probabilities of functional recovery (i.e., both po-
tent and continent) and 5-year probability of freedom
from BCR (P = 0.9) (Figure 2B). The present findingsB
Random effects variance = 0.0318 (95% CI 0.0125 – 0.1649, P = 0.001)
outcomes by surgeon. A. Probability of potency at 18 months
C. 5-year probability of freedom from biochemical-free recurrence.
re adjusted for patients with the mean level of the covariates: age at
f surgery and surgical experience. The vertical line represents the mean
ore ≥ 17, with alprostadil-users defined as impotent. Continence was
kage associated with physical activity.
ASpearman’s rank correlation -0.20 (95% CI -0.76 - 0.54, P = 0.61)
B
Spearman’s rank correlation 0.03 (95% CI -0.65 to 0.68, P = 0.93)
C
Spearman’s rank correlation -0.03 (95% CI -0.68 to 0.65, P = 0.93)
D
Spearman’s rank correlation 0.13 (95% CI -0.58 to 0.73, P = 0.73)
Figure 2 Scatter plots. A. Adjusted probability of continence and potency at 18 months postoperatively. B. Adjusted probability of functional
recovery and 5-year probability of freedom from biochemical recurrence at 18 months postoperatively. C. Adjusted probability of continence and
5-year probability of freedom from biochemical recurrence at 18 months postoperatively. D. Adjusted probability of potency and 5-year probability of
freedom from biochemical recurrence at 18 months postoperatively. Each circle represents a single surgeon and the size is proportionate to
the surgeon’s prior experience and the number of radical prostatectomies that surgeon performed during the study period.
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tional recovery and BCR was assessed separately; con-
tinence and potency, respectively (Figure 2C and 2D).
Discussion
In the present validation study, we explored whether
heterogeneity in long-term functional outcomes in a
European academic center is comparable to that previ-
ously reported in a very high-volume referral center in
the US [6]. Our data confirms prior studies on the exist-
ence of surgeon heterogeneity for continence, but not
for potency [5-7].
Continence rates were similar when comparing our
present study to the Vickers et al. study in which 1,910
patients were treated with RP by 1 of 11 surgeons between
1997 and 2007 at a high-volume US referral center [6],
with a rate of 85% at 18 months vs. 83% at 12 months,respectively. However, potency rates were lower in the
present study, with a rate of 19% at 18 months compared
to 43% at 12 months in Vickers et al. Overall, the rate of
impotence at 18 months postoperatively was high in the
present study, with less than two-thirds of patients being
potent preoperatively. The lower rate of potency is most
plausibly explained by the fact that the men in this study
were considerably older, with a median age of 64 years,
as compared to the median age of 58 years in the Vickers
et al. study. Another possible explanation is that the study
cohort was derived from a population-based sample in
an area where active surveillance is frequently used, im-
plying that only the most aggressive tumors are treated;
this likely results in more advanced tumor features lead-
ing to more radical surgery with wider resection and
lower potency rates. This is exemplified in that only one
third of patients underwent a bilateral nerve-sparing
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dication for nerve-sparing procedures may explain these
results.
A major strength of the current study is that potency
and continence outcomes were assessed from patient-
administered questionnaires in contrast to the study by
Vickers et al., where the same outcomes were evaluated by
the treating surgeon. PROs provide an assessment of func-
tional outcomes from the patient’s perspective. Therefore,
collecting data from the patient may protect against bias
due to patients minimizing symptoms when they are
asked by the treating physician directly. Published rates of
impotence after RP based on physician reports may be un-
derestimates, since patients may not report this side effect
accurately and completely to their doctor [11].
Furthermore, the patient-reported potency rate in the
present study is in line with other population-based series
on unselected patients in the literature [11-15]. In the
Scandinavian Prostate Cancer Group Study 4 (SPCG-4)
trial, the prevalence of ED 12 years after RP was 84% [3].
We found no evidence of heterogeneity in potency by
surgeon. Our failure to replicate a prior finding of hetero-
geneity for potency outcomes [6] may be related to a floor
effect of low overall rates as well as limited power (9 sur-
geons). Other possible explanations are that potency post-
operatively is more a question of inherent patient factors
or also dependent upon the individual decision of the sur-
geon and patient to elect for a nerve-sparing procedure.
For continence outcomes at 18 months, we found evi-
dence of significant heterogeneity between surgeons. The
difference was quite remarkable (7%–30% incontinence
rates). This finding is in line with a previous US study.
Using the SEER-Medicare database (patients ≥ 65 years
old); Begg et al. found that case mix-adjusted incontinence
rates 1 year after RP were lower in very high-volume
hospitals than in low-volume hospitals. They also stud-
ied, in detail, long-term incontinence in patients for 159
surgeons in the 2 highest-volume categories (20–32 RPs
per surgeon and 33–121 RPs per surgeon during the
study period) and noted significant surgeon-to-surgeon
variations in outcome [7].
Urinary incontinence and impotence after RP have a
major impact on QoL [4] and these side effects, espe-
cially in the long-term, are one of the major drawbacks
of PSA screening [16]. In the present study the average
incontinence rate was 15%, which is very similar to the
17% reported by Vickers et al. [6]. The large variation
between surgeons suggests a need for formal quality as-
surance programs and performance feedback systems.
Surgeons need to know their results so that they can
evaluate and find ways to improve them [17].
Previous studies have shown heterogeneity between
surgeons regarding not only functional outcomes but also
risk for BCR and clinical recurrence [5,6,18]. In particular,Vickers et al. found that functional preservation did not
come at the expense of cancer control [6]. Indeed, there
was a positive correlation between oncologic and func-
tional outcomes, suggesting that both are markers of sur-
gical quality. We were not able to replicate this finding,
possibly due to a floor effect for potency.
Conclusion
RP is associated with long-term side effects such as incon-
tinence and ED. In this study we replicated prior findings
that individual surgeon technique is related to the risk of
permanent incontinence; we were unable to replicate find-
ings relating surgical technique to erectile dysfunction and
oncologic outcome. Quality assurance measures involving
performance feedback should be considered. When sur-
geons are aware of their outcomes, they can improve them
to provide better care to patients.
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